Showing 1551-1560 of 9707 results for "".
PDT: Patient Profiles for a Practice-changing Treatment
https://practicaldermatology.com/series/pdt-in-practice/pdt-patient-profiles-for-a-practice-changing-treatment/20186/Who's the ideal candidate for PDT? Other options, limitations? The advances in PDT both doctors and patients would like to see are described by Corey Hartman, MD, who shares his experiences and relates how PDT has improved his practice.Currents: Updates and Innovations
https://practicaldermatology.com/topics/infections-infectious-disease/currents-updates-and-innovations/23832/The World Health Organization (WHO) will begin using “mpox” as a synonym for monkeypox. Both names will be used simultaneously for 1 year while “monkeypox” is phased out.Choosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.Platform Unites Dermatologists to Address Rising Drug Costs
https://practicaldermatology.com/topics/practice-management/platform-unites-dermatologists-to-address-rising-drug-costs/23781/How a digital platform brought together a specialty.Landing in Dermatology
https://practicaldermatology.com/series/scientifically-speaking/landing-in-dermatology/20129/Humberto Antunes talks to host Joel L. Cohen, MD about how he got his start in dermatology and why the field appealed to him.DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eConsidering a Role for Oral JAK Inhibitors in AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/considering-a-role-for-oral-jak-inhibitors-in-ad-care/23745/The newest class of treatments for AD expands the possibilities to achieve and maintain skin clearance.In the Pipeline: New Approaches to Vitiligo, Congenital Ichthyosis, and More
https://practicaldermatology.com/topics/pigmentary-disorders/in-the-pipeline-new-approaches-to-vitiligo-congenital-ichthyosis-and-more/23714/Inflammatory diseases with few or no specific treatments may soon have approved interventions.Emerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iTips for Filling the Jaw, Chin, and Mid-face
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/tips-for-filling-the-jaw-chin-and-mid-face/23598/CSF faculty members share pearls for injecting new fillers.